Company Description
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders.
Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract.
The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia.
Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
| Country | United States |
| IPO Date | Dec 23, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Dr. Milton H. Werner Ph.D. |
Contact Details
Address: 3350 Riverwood Parkway Se, Suite 1900 Atlanta, Georgia 30339 United States | |
| Phone | 678-392-3419 |
| Website | inhibikase.com |
Stock Details
| Ticker Symbol | IKT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001750149 |
| CUSIP Number | 45719W106 |
| ISIN Number | US45719W2052 |
| Employer ID | 26-3407249 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Charles Warren Olanow B.Sc., F.R.C.P.C., M.D. | Chief Executive Officer of Clintrex Research Corporation and Member of Scientific Advisory Board |
| Dr. Milton H. Werner Ph.D. | Chief Executive Officer, President and Director |
| Garth Lees-Rolfe | Chief Financial Officer |
| Dr. Roger Rush | Head of Preclinical Research |
| Dr. Surendra Singh | Head of Chemistry, Manufacturing and Controls |
| Dan Williams | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 27, 2024 | 424B3 | Prospectus |
| Jun 26, 2024 | EFFECT | Notice of Effectiveness |
| Jun 21, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 20, 2024 | DEF 14A | Other definitive proxy statements |
| Jun 18, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 10, 2024 | PRE 14A | Other preliminary proxy statements |
| Jun 10, 2024 | 8-K | Current Report |
| Jun 4, 2024 | D | Notice of Exempt Offering of Securities |
| May 22, 2024 | 424B5 | Filing |
| May 20, 2024 | 8-K | Current Report |